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The development of drugs in the generic pharmaceutical industry is
a highly competitive arena of companies vying for few drug
products that are coming o¡ patent. Companies that have been
successful in this arena are those that have met or surpassed the
critical timeline associated with trial formulation development,
analytical method development, and submission batch manufactur-
ing and testing. Barr Laboratories Inc., has been successful in the
generic pharmaceutical industry for several reasons, one of which
includes automation. The analytical research and development at
Barr has employed the use of automated dissolution early in the
lifecycle of a potential product. This approach has dramatically
reduced the `time to market’ on average for a number of products.
The key to this approach is the network infrastructure of the
formulation and analytical research and development departments.
At Barr, the cooperative ability to work and communicate together
has driven the departments to streamline and matrix their work
e¡orts and optimize resources and time. The discussion will
reference how Barr has been successful with automation and gives
a case study of products that have moved with rapid pace through
the development cycle.
Introduction
Barr Laboratories, Inc., has been a competitive player in
the manufacture of generic pharmaceuticals as well as
proprietary products. One of the pillars of success has
been the cooperative eå ort of the product development
and analytical development teams. In the generic realm,
companies who have been successful in the marketplace
are those who have seized an opportunity for a viable
product candidate, and been able quickly to expedite the
development of that product and submit for approval. In
the race for generic pharmaceuticals, there is no second
place. Companies who come in second risk low market
share for their product and, therefore, very little pro® t
margin, if any.
The critical success factor becomes the speed in which a
biobatch formulation can be manufactured, the analyti-
cal method developed and validated, and the biobatch or
clinical batch tested and submitted to the agency.
Product lifecycle
To gain a better understanding of where gains in the
development and validation process can be made, one
must ® rst understand the product lifecycle time line
(® gure 1). First, new drug candidates are selected based
on market volume, need for specialty manufacturing
facilities and or techniques (i.e. narrow therapeutic range
drug and others), and complementing existing product
lines. Next, the candidates are selected and the products
kicked oå with a launch meeting which provides in-
formation about the therapy for the new product,
establishing development time frames, identifying issues
with development and validation, resolving issues with
raw material and excipient availability, and con® rming a
clinical research organization for the biostudy or clinical
study. At this point the evaluation/development work on
the brand product begins, as well as the initial formula-
tions from the product development side.
Once trials have been tested, preliminary decisions are
made as to the direction for the analytical methodology.
Automation usually enters the picture at some point close
to the ® nal formulation. Once the ® nal formulation is
reached, it is scaled up and the analytical validation
proceeds along with the validation of the automated
methodology. At just about the same time, both the
manual and automated methods are completed and
updated as the established methods for testing and
releasing the product. The biobatch is made and the
process validation tested by the established methods. The
stability study follows at the predetermined time-points,
the product is submitted to the FDA, and the methods
are transferred to the quality control department.
Statistical design
The product development team utilizes several tools to
enhance its ability to provide a formulation for testing.
One is the use of mathematical models for formulation
design. The basic goal in utilizing statistical design is to
optimize a formulation. The most readily used design
schemes are the factorial design and the simplex design.
These design schemes allow the formulation scientist to
vary certain independent parameters while monitoring
other dependant parameters.
The simplex lattice design is a relatively new design in
pharmaceutical research but is quite eå ective (® gure 2).
The basis of this design scheme is that there is a con-
straint on the mixtures of components. The total amount
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173of the varying ingredients under evaluation must also
sum to unity. The components of the design are then
arranged in one of several lattice con® gurations based on
the model for that product. Mathematically, the model is
represented by polynomials. Using the polynomials;
equations, predictive information about the model can
be achieved in a short period with a limited number of
test cases.
Figure 1. Product lifecycle time line.
Figure 2. Lattice structures.
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graphical constructs. For mixtures containing three com-
ponents, a triangle can be used, and for four components,
a tetrahedron. With more than four components it
becomes increasingly diæ cult to represent a fourth di-
mension and higher visually, but it can be represented by
an n-sided ® gure in an (n ¡ 1) dimensional space. How-
ever, the ability to uncover information about the blend
of components comes by investigating the entire ranges of
the composition, which is represented by the ordered
arrangements of the lattice structure. The responses or
features are measured at the lattice points and equations
representing those reponses are derived. Calculations are
performed and resultant statistics give predictive infor-
mation as to the suitability of the model for that product.
Overall, these design schemes make it possible to choose a
small number of informative test cases that will allow the
formulation scientist quickly to resolve a formulation
with the desired properties. With these abilities, the
formulation scientists can make several lots of product
initially and submit them to the analytical laboratory for
testing. The information gained from these trials allows
them to make an informed decision as to the direction of
their formulation work. At this point, the samples are
submitted to the analytical laboratory for analysis.
Automation approach
The Analytical Research and Development (AR&D)
laboratory at Barr handles all method development and
testing of trial batches produced by the product devel-
opment (PD) formulation scientists. Up until a restruc-
turing of AR&D, all method development and validation
of automated methods did not start until the beginning of
the scale-up manufacturing phase (® gure 1).
This approach had signi® cant gains in the management
of work ¯ ow for the individual teams whose project was
being automated. In many cases, the scale-up testing and
biobatch were tested completely using automation. This
allowed other members of the team to concentrate on
more diæ cult and time-consuming tasks. As a pro-
ductivity tool, automation had scored A’ s. However, in
the category of increasing the number of submissions to
the agency, automation was scoring very low.
It was not until the management of the AR&D looked at
how and where automation was being implemented that
there would be changes in the way in which automation
would be utilized to increase the number of submissions.
That change in perspective caused a shift in the way in
which projects would be evaluated and distributed
among the diå erent AR&D teams. The new view was
to hand-pick projects at launch meeting time that would
be good candidates for automation. Then, from the start
of the product development trial formulation phase, all
work submitted to the AR&D laboratory for dissolution
or assay and CU testing would be tested using automated
means.
The ® rst product to use this approach was launched in
record time for Barr. The time from launch meeting to
submission was 6 months (including the 3-month stability
time-point). Each additional product that has utilized
this approach has been expedited as a result of the quick
sample turn around. Why was Barr so successful in this
approach? The answer in the infrastructure of the com-
pany and the successful experience of veteran automation
users provided with the right tools.
Infrastructure
The infrastructure of Barr is such that a large number of
projects can be handled by the individual development
teams (® gure 3). In turn, these development teams
correspondingly work with the AR&D teams for devel-
opmental testing of their formulations. Not only does this
approach lend itself well to highly parallel development
of products, but the skill sets of each group get developed
and most optimally utilized within their respective
environment.
The work¯ ow (® gure 4) comes as a function of the PD’ s
submission of samples to the AR&D laboratory for
analysis. By changing the entrance of automation to the
beginning of the project, trials could be evaluated util-
izing automated systems. PD’ s approach to submitting
samples has changed as well. The open lines of commu-
nication, matrix design schemes and the high-volume
capacity of automation has caused an acceleration in
the development timeline for products. Utilization of
automation has increased the volume of information
Figure 3. Infrastructure at Barr.
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the product.
Automation tools
Analytical R&D has made use of several automation
resources in its eå orts to push the envelope of the critical
timeline associated with launching new generic and
proprietary products. One of the most useful tools has
been the automated dissolution workstation (® gure 5).
We have employed the use of Zymark’ s Multidose
Automated Dissolution Workstation (MADW) as the
centrepoint of Barr’ s streamlining approach at launching
products.
Some of the key features of the multidose that make it
suited for high throughput analysis are its ability to run
up to eight batches without reloading, to utilize four
diå erent media and DI H2O, to run either apparatus I or
II to collect samples in vials or test tubes, or to run
utilizing on-line UV analysis.
The coordination of the interdepartmental communica-
tion is the most important factor that has allowed all of
the pieces to work together to optimize turnaround time.
Our approach in this area has been to set-up the devel-
opment project with the PD department in such a way
that high-volume testing is part of the resource for testing
samples. With this in mind, the formulation scientists
have utilized the diå erent statistical design models to
submit groups of samples to be analyzed with several
diå erent media. The batch analysis approach has shown
the eå ectiveness of the automation tools by providing
large volumes of development information in a relatively
short period.
E‡ ciencies
The old approach in development was to submit a
sample or two to the laboratory for analysis. The next
day, results would be generated and submitted for review
by the formulation scientists. Upon their review, deci-
sions as to the results would be made and another one or
two samples would be submitted to the laboratory for
analysis on the following day. After 1 week, only about
six trials would have been made and tested.
In the new approach, a set of samples of beween four and
eight would be submitted for analysis in media ranging
from 0.1N HCl through the pH range to pH 8.0 buå er.
The results of these analysis would generally be sub-
mitted by 10:00 hours the next day and we could expect
to receive more trial samples to analyse by late that day.
In eå ect, the company could formulate, analyse, calcu-
late and review, and reformulate within 24h.
As a result, the projects have begun to move rapidly
through the development and validation stage. These
changes have also aå ected the other areas of the company
causing them to streamline their eå orts to keep pace with
Figure 4. Work£ow at Barr.
Figure 5. Automatch dissolution workstation.
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also increased steadily as the information technology
(IT) department has implemented systems to improve
data analysis and report generation.
Case studies
Currently, there are several projects that have bene® ted
from the use of automated dissolution. The products
themselves range in the several categories of therapy. In
each case, the approach was the same: to implement the
use of automated dissolution from the project inception to
the completion of the submission.
Three of the products were developed using on-line UV
analysis. The other product was oå -line LC collection
into vials. For the products that used on-line UV
analysis, there was an added bene® t of additional time-
point analysis that compromised no eæ ciency in the
throughput. It was not more diæ cult to analyse the
dissolution at 5-min intervals than at 30-min intervals.
This allowed for a greater number of sampling points to
provide the formulation scientists with more data about
the dissolution analysis. The initial dissolution work for
all product was conducted by running a series of dissolu-
tion analysis of the brand product by both basket and
paddle in several media representing the pH of the
gastrointestinal tract. This information coupled with
diå ering RPM and peak vessel combinations provided
a wide spectrum of detailed information about the nature
of the brand product. For the example mentioned above,
the development time for Barr’ s formulation was just
under 6 weeks. This compressed timeline was achieved
because of the volume of data generated early in the life
of the project. A ® nal formulation was achieved and
con® rmed, and a series of additional dissolution tests in
diå erent media conducted to con® rm the desired pro® le.
Shortly thereafter, a scale-up formulation was manufac-
tured and tested. All of the analytical methods (both
manual and automated) were validated and all samples
for the biobatch were analysed using the automated
methodology. The project from start to submission,
including the 3-month stability time-point interval, was
6 months. Compare that with the usual 9± 18 month
timeline for product development and submission.
To be realistic, not all products can follow such an
aggressive pace. There are raw material and excipient
availability problems that need to be contended with as
well as issues that arise from manufacturing and analy-
tical areas. Two of the product currently in the pipeline
for automation have experienced these problems and
have slowed the pace somewhat, but in the grand scheme
of projects, that has allowed an opportunity to evaluate
and develop other products in the interim.
The remaining product has been placed on a fast track
and has been developed to date in a record time: 3 weeks.
This project is far from complete, but ® nal formulation
will be soon to arrive and this project should be sub-
mitted by early 2001. That would be a 5-months devel-
opment and submission timetrame.
Conclusion
The use of automation in the analytical research and
develoment department has been a major factor in
expediting the formulation development process. How-
ever, it is not the sole factor for the success. Barr
Laboratories, Inc., success at expediting product devel-
opment is attributed to its corporate commitment to
bringing healthcare products to the market quickly.
The cooperation of the diå ering departments in working
toward the goal of accelerated development has been the
key to making the process successful.
Barr continues to look at new technology and new
approaches to improving and accelerating product devel-
opment and will continue to invest in those areas that will
allow it to do so.
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